PPG sets science-based 2030 decarbonization targets, reports 2022 sustainability progress
31.5.2023 17:15:00 EEST | Business Wire | Press release
PPG (NYSE:PPG) today announced its near-term 2030 sustainability goals, including greenhouse gas (GHG) emissions targets that have been validated by the Science Based Targets initiative (SBTi). The company also marked strong progress against its environmental, social and governance (ESG) priorities, reporting increased sales of sustainably advantaged products, more efficient operations, strong momentum towards achieving diversity, equity and inclusion goals, greater supplier sustainability and strengthened support within communities where the company operates.
“PPG has long been committed to reducing the environmental impact of its own operations, and we are proud to have validated science-based GHG emissions targets that are in line with the expectations of the Paris Agreement,” said Diane Kappas, PPG vice president, global sustainability. “By raising our sustainability ambitions and increasing sales of sustainable solutions for our customers, PPG is advancing its leadership in the paints and coatings industry.”
PPG has committed to reduce absolute emissions from its own operations (scope 1 and 2) by 50% by 2030 from a 2019 base year. It has also committed to reduce absolute scope 3 GHG emissions from purchased goods and services, processing of sold products, and end-of-life treatment of sold products by 30% within the same timeframe. The company’s emissions reduction strategy for its own operations includes energy efficiency projects and renewable energy sourcing. Within the value chain – or scope 3 – PPG is collaborating with suppliers to identify GHG emissions reduction opportunities and lower-carbon raw material sources. PPG recently signed an agreement with NRG Energy Inc. that will enable four PPG paints and coatings manufacturing facilities and 62 PPG PAINTS™ stores in Texas to operate on 100% renewable electricity.
In addition to its science-based emission targets, PPG’s other 2030 ESG targets against a 2019 baseline are:
- 50% of sales from sustainably advantaged products
- 15% reduction in water intensity at priority sites
- 25% reduction in waste intensity
- Reuse, recycle or recover 100% of process waste
- $5 million additional COLORFUL COMMUNITIES® funding, with each project incorporating an element of sustainability, making the total investment $15 million since 2015
- 100% of key suppliers assessed against sustainability and social responsibility criteria
- 100% of employees go home safely each day
- 5% annual reduction in spill and release rate
Furthermore, the company outlined key progress from the 2022 reporting year including:
- Developing sustainable innovations that meet customers’ greatest needs, such as the launch of PPG INNOVEL® PRO, a non-bisphenol/non-BPA coating that ensures minimal spoilage and protection for aluminum beverage cans, while promoting circularity.
- Collaborating with Steelcase, a U.S. manufacturer of architecture, furniture and technology products, to further increase the circularity of PPG powder coatings. PPG developed processes to recycle powder overspray into new coatings, which Steelcase uses on brackets, inside drawers and other less-visible surfaces in its products.
- Continued investment in PPG’s signature Colorful Communities initiative. The company marked more than 470 projects, impacting more than 8 million people since 2015.
-
Strong improvement against 2025 diversity, equity and inclusion aspirational goals, including:
- 19% increase in U.S. non-frontline Black headcount
- 16% increase in U.S. non-frontline Latino headcount
- 8% increase in U.S. non-frontline Asian headcount
- 31% representation of non-frontline female professionals; a 180 basis-point improvement from 2021
“We remain committed to our journey of fostering a more diverse and inclusive community both within and beyond PPG,” said Marvin Mendoza, PPG global head, diversity, equity and inclusion. “We know that diverse teams perform better, and our 2022 progress is enabling a more equitable, inclusive future where employees feel even more empowered to bring their whole selves to work.”
Additional 2022 progress is outlined in further detail in PPG’s just-released 2022 Environmental, Social and Governance (ESG) Report at ppg.com/sustainability.
The Science Based Targets initiative (SBTi) mobilizes companies to set science-based targets and boost their competitive advantage in the transition to the low-carbon economy. It is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi call to action is one of the We Mean Business Coalition commitments. The initiative defines and promotes best practice in science-based target setting, offers resources and guidance to reduce barriers to adoption, and independently assesses and approves companies’ targets.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
PPG Paints is a trademark and Colorful Communities, Innovel, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Sustainability
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005110/en/
Contact information
Greta Edgar Borza
Corporate Communications
+1 724 316 7552
edgar@ppg.com
www.ppg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
